JSW Group to procure vaccines for 25,000 employees and their families
ECONOMY & POLICY

JSW Group to procure vaccines for 25,000 employees and their families

As an initial step in the process of inoculating employees against Covid-19, JSW Group, a few Tata Group companies, the India unit of a major multinational, and numerous other firms have plans to begin talks with vaccine manufacturers. The employees working at manufacturing units are more vulnerable than those working from home, and will receive priority treatment.

The first shots of the vaccine will be available from as early as March. According to sources, around two to three lakh doses will be supplied. Serum Institute of India began delivering its Covishield vaccines last week, followed by Bharat Biotech with the homegrown Covaxin. The initial focus is to vaccinate healthcare and frontline professionals by July.

Tata Group said that some of the companies in the conglomerate have initiated discussions on procuring vaccines, but a decision hasn't been taken yet, as informed by sources.

The India unit of a multinational manufacturing company is awaiting communication from the parent, which has initiated talks with global vaccine manufacturers for its units in North America and Europe.

Instead of depending on Serum Institute and Bharat Biotech alone, companies are waiting for more vaccines to come into the market. Four other companies are in different stages of conducting trials including Russia's Sputnik vaccine that will be distributed by Dr Reddy's Lab in India, and Zydus Cadila, which recently got the nod for third phase trials.

As companies await better clarity on the supply of vaccines, some wonder whether vaccination of employees could be included under corporate social responsibility.

Image source

As an initial step in the process of inoculating employees against Covid-19, JSW Group, a few Tata Group companies, the India unit of a major multinational, and numerous other firms have plans to begin talks with vaccine manufacturers. The employees working at manufacturing units are more vulnerable than those working from home, and will receive priority treatment. The first shots of the vaccine will be available from as early as March. According to sources, around two to three lakh doses will be supplied. Serum Institute of India began delivering its Covishield vaccines last week, followed by Bharat Biotech with the homegrown Covaxin. The initial focus is to vaccinate healthcare and frontline professionals by July. Tata Group said that some of the companies in the conglomerate have initiated discussions on procuring vaccines, but a decision hasn't been taken yet, as informed by sources. The India unit of a multinational manufacturing company is awaiting communication from the parent, which has initiated talks with global vaccine manufacturers for its units in North America and Europe. Instead of depending on Serum Institute and Bharat Biotech alone, companies are waiting for more vaccines to come into the market. Four other companies are in different stages of conducting trials including Russia's Sputnik vaccine that will be distributed by Dr Reddy's Lab in India, and Zydus Cadila, which recently got the nod for third phase trials. As companies await better clarity on the supply of vaccines, some wonder whether vaccination of employees could be included under corporate social responsibility. Image source

Related Stories

Gold Stories

Next Story
Resources

Schindler named among Forbes’ World’s Best Employers 2026

Schindler has been named among Forbes’ World’s Best Employers 2026, a global ranking recognising companies for their workplace environments.Compiled by Forbes in partnership with Statista, the ranking is based on independent employee feedback, including whether employees would recommend their organisation to friends and family.The company said the recognition reflected its focus on creating a workplace where employees can develop their expertise and build careers. ..

Next Story
Infrastructure Urban

India needs an export-execution mindset: Vishesh Jain

Interview with Vishesh Jain, Founder & CEO, EximpleWhat gaps in India’s global trade ecosystem led you to build Eximple, and what problem did you see businesses struggling with most?Eximple came out of a problem that all three founders had seen from different choke points in the trade ecosystem. India has millions of MSMEs and manufacturers, and many of them can make products that are genuinely competitive on quality. Yet only a small fraction is able to build meaningful international businesses. In our experience, the gap is usually not manufacturing capability; it is the ability to exe..

Next Story
Building Material

Nuvoco reports 13.5% revenue growth in Q2 FY27

Nuvoco Vistas Corp. Ltd. reported consolidated revenue of Rs 27.9 billion for Q2 FY27, up 13.5% year on year. Cement sales volume rose 9% to 4.7 million tonnes (MMT), while EBITDA increased 11% to Rs 4.11 billion.The company said it began its cement operations in 2014 with a 2.3 MMT per annum (MMTPA) operation at Nimbol. It now aims to reach 35 MMTPA of cement capacity by FY28, nearly 15 times its initial capacity. Its portfolio spans cement, ready-mix concrete and modern building materials.On sustainability and cost efficiency, Nuvoco partnered with CleanMax for a 46.4 MW wind-solar hybrid re..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

SPECIAL OFFER
QR Code